Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.

Bruker Corporation

In a report released today, Luke Sergott from Barclays maintained a Buy rating on Bruker, with a price target of $55.00. Sergott covers the Healthc...

Barclays Keeps Their Buy Rating on Bruker (BRKR)

Bruker ( ($BRKR) ) just unveiled an update. In a recent regulatory filing, Bruker clarified that certain information furnished in Item 2.02 and Ite...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BRKR	$42.57	-2.70%	648.03K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BRKR	$42.57	-2.7%	648.03K
3
4
5
6

BRKR

BRKR

Latest News for BRKR

Get Bruker Corporation Data in Excel

Get Bruker Corporation Data in Excel